Videssa®
BREAST



Finally, the blood test that detects breast cancer.™

Videssa BREAST — The First and Only Blood Test for EARLY BREAST CANCER DETECTION.

A critical need to enhance breast imaging technologies.

Current methods of detection do not meet the needs of all patients, specifically women with abnormal or difficult-to-interpret imaging findings.

80-90% of annual breast biopsies are benign[1,2]

↑ **False Positives**

30-40% of breast cancers go undetected in women with dense breasts[3]

↑ **False Negatives**



Videssa® Breast: A New Diagnostic Complement to Imaging

When considering biopsy or advanced imaging, Videssa Breast provides additional information for greater confidence in clinical decision-making.

Biopsy?

- **Anxious patient:** *BI-RADS 3, insists on biopsy*
- **Elevated Risk:** *BI-RADS 3 or abnormal imaging, think it's benign but family history, etc.*

Advanced Imaging?

- **Dense Breasts:** *Difficult-to-interpret imaging, lesion may be obscured*

Videssa® Breast Performance

In two prospectively collected, blinded, randomized, multi-center clinical trials (Provista 001 and Provista 002-Cohort 1), Videssa Breast demonstrated the ability to detect the presence or absence of breast cancer and/or DCIS in women with a BI-RADS® 3 or 4 assessment on imaging, irrespective of breast density.

Provista Trial 001 (n = 339, women ages 25-49)

True Positive	True Negative	False Positive	False Negative	Sensitivity	Specificity	NPV	PPV
24	267	46	2	92.3%	85.3%	99.3%	34.3%

- Videssa Breast correctly identified **24/26** total invasive breast cancer and DCIS cases, yielding a **sensitivity of 92.3%**.
- Videssa Breast correctly identified **267/313** benign cases, yielding a **specificity of 85.3%**.

High NPV: Increased confidence in negative test results

Provista Trial 002 - Cohort 1 (n =492, women ages 25-75*)

True Positive	True Negative	False Positive	False Negative	Sensitivity	Specificity	NPV	PPV
48	365	72	7	87.3%	83.5%	98.1%	40.0%

- Videssa Breast correctly identified **48/55** total invasive breast cancer and DCIS cases, yielding a **sensitivity of 87.3%**.
- Videssa Breast correctly identified **365/437** benign cases, yielding a **specificity of 83.5%**.

Videssa Breast Signature

Tumor Associated Autoantibodies (TAAbs) + **Serum Protein Biomarkers (SPBs)** + **Patient Clinical Data** = Videssa BREAST

- ➢ High Specificity
- ➢ High Sensitivity
- ➢ Age-Adjusted

Videssa Breast delivers binary test results, reported as either:

Low Protein Signature: confirms the absence of breast cancer, providing confidence that additional procedures (diagnostic imaging and/or biopsy) may not be warranted

High Protein Signature: may indicate the presence of breast cancer, and will likely prompt further clinical follow-up (additional diagnostic imaging and/or biopsy)

*Analysis of Provista Trial 002-Cohort 1 comprising of women ages 25 – 75 revealed distinct age-dependent clusters of SPB and TAAb biomarkers (ages 25 – <50 and 50 – 75). These age-dependent responses resulted in the development of an unique model with distinct set of biomarkers; results for the analysis of 286 women ages 50 – 75 from Provista Trial 002-Cohort 1 are as follows: Sensitivity 89.8%, Specificity 83.5%, NPV 97.5%, and PPV 53.0%.

Videssa BREAST

The blood test that detects breast cancer.™

Streamline the clinical decision pathway.

Videssa Breast helps indicate patients who may warrant further evaluation, by providing a biochemical signature which complements anatomical imaging views. This integrative approach allows for improved diagnostic accuracy and greater confidence when clinical assessment is challenging.

- **The first and only blood test for the early detection of breast cancer**
- **Provides highly reliable, clinically-actionable test results**
- **An important diagnostic complement to the known limitations of current imaging studies**
- **Can significantly reduce the number of false positive biopsies**
- **Increases clinical confidence, clarity, and peace of mind**

For more information on Videssa Breast or Provista Diagnostics, please visit ProvistaDx.com.

Provista Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address unmet needs in breast and gynecologic cancers.

Provista DIAGNOSTICS®
Precision Diagnostics to Enhance Women's Health

Provista Diagnostics, Inc.
17301 North Perimeter Drive, Suite 100, Scottsdale, AZ 85255
Tel: 1-855-552-7439
ClientServices@ProvistaDx.com

www.ProvistaDx.com

References:
[1] Gur D,Wallace LP, Klym AH, et al. Trends in Recall, Biopsy, and Positive Biopsy Rates for Screening Mammography in an Academic Practice. Radiology 2005 235:2, 396-401.
[2] Data on file with Provista Diagnostics, Inc.
[3] Wang AT, Vachon CM, Brandt KR, et al. Breast Density and Breast Cancer Risk: A Practical Review. Mayo Clin Proc. 2014;89(4):548-557.